It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A clinical-stage company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies
- LPCN also has an extended-release (ER) version of Tlando that is entering a P3 study
- Other programs:
- LPCN 1144 (in P2 for NASH)
- LPCN 1148 (entering P1 for cirrhosis)
- LPCN 1107 (entering P3 for the prevention of recurrent preterm birth)